Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

1
Player Avatar irishred1 (< 20) Submitted: 3/19/2011 9:48:06 PM : Outperform Start Price: $14.38 SGEN Score: +72.49

unique antibody drug conjugate technology with many big pharma partnerships...first candidate about to gain approval if the FDA isn't phased by the single arm trial design. I see nothing but upside long term

Report this Post Reply

Featured Broker Partners


Advertisement